RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the incidence, clinicopathological characteristics, treatment outcomes, prognostic factors, and survival of gastriccancer patients with bone metastases.

Materials and Methods: Of 4,617 gastric cancer patients who were treated between 2001 and 2013, 176 patients with bone metastaseswere analyzed.

Results: The incidence of bone metastasis was 3.8%. The most common histopathological subtype was adenocarcinoma (79%) withpoor differentiation (60.8%). The median interval from the diagnosis to bone metastasis was 11 months. The median survival time afterbone metastasis was 5.4 months. Factors that were associated with longer median survival times included the following: isolated bonemetastasis (P=0.004), well-differentiated tumors (P=0.002), palliative chemotherapy (P=0.003), zoledronic acid treatment (P<0.001),no smoking history (P=0.007), and no metastatic gastric cancer at the time of diagnosis (P=0.01). On the other hand, high levels oflactate dehydrogenase (LDH) (hazard ratio [HR]: 1.86; P=0.015), carcinoembryonic antigen (CEA) (HR: 2.04; P=0.002), and carbohydrateantigen (CA) 19-9 (HR: 2.94; P<0.001) were associated with shorter survival times. In multivariate analysis, receiving zoledronicacid (P<0.001) and performance status (P=0.013) were independent prognostic factors.

Conclusions: Smoking history, poor performance status, poorly differentiated adenocarcinoma, and high levels of LDH, CEA, and CA19-9 were shown to be poor prognostic factors, while receiving chemotherapy and zoledronic acid were associated with prolonged survivalin gastric cancer patients with bone metastases.

참고문헌 (Reference)

1 Batson OV, "The function of the vertebral veins and their role in the spread of metastases. 1940" (312) : 4-9, 1995

2 Hundahl SA, "The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis" 88 : 921-932, 2000

3 Nakanishi H, "Skeletal metastasis in patients with gastric cancer" (423) : 208-212, 2004

4 Silvestris N, "Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey" 8 : e74402-, 2013

5 Kobayashi M, "Metastatic bone cancer as a recurrence of early gastric cancer -- characteristics and possible mechanisms" 11 : 5587-5591, 2005

6 Kılıçkap S, "Metastasis to bone from gastric cancer: a single centre experience" 32 : 192-198, 2010

7 Lehnert T, "Lymph and blood capillaries of the human gastric mucosa. A morphologic basis for metastasis in early gastric carcinoma" 89 : 939-950, 1985

8 Aapro M, "Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel" 19 : 420-432, 2008

9 International Agency for Research on Cancer, "Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012" International Agency for Research on Cancer

10 Jemal A, "Global cancer statistics" 61 : 69-90, 2011